Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

Two Peer-Reviewed Articles Supports The Clinical Performance Of Predx Diabetes Risk Score

Tethys Bioscience, Inc which has developed a novel tool to help clinicians identify and focus resources on those individuals at highest risk of developing type 2 diabetes within five years, announced the publication of two peer-reviewed articles that support the science behind and clinical performance of that tool, the PreDx Diabetes Risk Score.

In an article Tethys researchers and their academic and medical collaborators demonstrate the validity of the research model that informed development of the PreDx Diabetes Risk Score. The PreDx Diabetes Risk Score incorporates multiple biomarkers from several biological pathways implicated in the development of diabetes to estimate progression to the disease in a given population. The Diabetes Care paper demonstrates the superiority of this approach, when compared to single-risk indicators or clinical models, at estimating 5-year risk of progression to type 2 diabetes.

Tethys also demonstrated the performance of the PreDx Diabetes Risk Score test in the clinical laboratory setting in another publication. The study, conducted in the Tethys Bioscience Clinical Lab, demonstrates that the PreDx Diabetes Risk Score is better at risk prediction than impaired fasting glucose, a clinical risk index, or metabolic syndrome, methods that are used to assess likelihood of developing the disease.

The more accurate and convenient measure of type 2 diabetes risk stratification offered by the PreDx DRS provides a valuable tool for clinicians to use in conjunction with clinical factors to identify individuals with the highest risk of developing diabetes in five years, the authors say. These individuals are those for whom prevention programs may reduce the serious health consequences of type 2 diabetes.

These publications add to a growing body of scientific and clinical evidence in support of the PreDx Diabetes Risk Score, said Mickey Urdea, Tethys’ CEO. Beyond these foundational studies, company have amassed one of the world’s largest collections of blood samples with known cardiometabolic outcomes from a number of significant studies with multi-ethnic US and international populations, and will use these resources to augment the current body of data with new insights that support the utility of the PreDx Diabetes Risk Score in broad, pan-ethnic populations. In addition, company is planning many more publications concerning ongoing studies and the application of these clinical samples to a pipeline of Tethys products based on the company’s technology.